Research Article

Gene Therapy (2003) 10, 1099–1104. doi:10.1038/sj.gt.3301978

Sustainable correction of junctional epidermolysis bullosa via transposon-mediated nonviral gene transfer

S Ortiz-Urda1, Q Lin1, S R Yant1, D Keene2, M A Kay3 and P A Khavari1

  1. 1Veterans Affairs Palo Alto Healthcare System and the Program in Epithelial Biology, Stanford University School of Medicine, Stanford, CA, USA
  2. 2Shriners Hospital for Children, Portland, OR, USA
  3. 3Departments Pediatrics and Genetics, Stanford University School of Medicine, Stanford, CA, USA

Correspondence: Dr PA Khavari, Program in Epithelial Biology, Stanford University School of Medicine, 269 Campus Drive, Room 2145, Stanford, CA 94305, USA

Received 8 August 2002; Accepted 6 December 2002.

Top

Abstract

Sustainable correction of severe human genetic disorders of self-renewing tissues, such as the blistering skin disease junctional epidermolysis bullosa (JEB), is facilitated by stable genomic integration of therapeutic genes into somatic tissue stem cells. While integrating viral vectors can achieve this, they suffer from logistical and biosafety concerns. To circumvent these limitations, we used the Sleeping Beauty transposable element to integrate the LAMB3 cDNA into genomes of epidermal holoclones from six unrelated JEB patients. These cells regenerate human JEB skin that is normalized at the level of laminin 5 protein expression, hemidesmosome formation and blistering. Transposon-mediated gene delivery therefore affords an opportunity for stable gene delivery in JEB and other human diseases.

Keywords:

skin, epidermolysis bullosa, gene therapy

Extra navigation

.

naturejobs

ADVERTISEMENT